Searched for
SHARVIL P PATEL
Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- Zydus launches biosimilar for ophthalmic careZydus Lifesciences has introduced Anyra, its first indigenously developed biosimilar for the treatment of visual impairment in India. This ...
- Zydus launches biosimilar for treatment of multiple cancersZydus Lifesciences has launched Tishtha, the world's first biosimilar of Nivolumab, in India. This drug treats multiple cancers. Tishtha wi...
- Hold Zydus Lifesciences, target price Rs 1,090: JM FinancialJM Financial maintains a hold rating on Zydus Lifesciences, setting a target price of Rs 1,090. The quarterly income has dropped by 15.40% ...
- Zydus inks licensing pact with Takeda to sell GERD drug"With a rich legacy in marketing gastrointestinal therapies in India, we have been offering different breakthrough clinical options across ...
- Buy Zydus Lifesciences, target price Rs 530: Yes SecuritiesBullish ABC breakout suggests follow through moves on P&F chart.
- Buy Zydus Lifesciences, target price Rs 572: Sharekhan by BNP ParibasZydus Lifesciences, incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 46161.57 Crore) operating in Pharmaceu...
- Buy Zydus Lifesciences, target price Rs 488: HDFC SecuritiesStock price is in an attempt of decisive upside break-out of resistance of top of Nov at Rs 454 levels.
- Buy Zydus Lifesciences, target price Rs 470: JM FinancialZydus Lifesciences Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 42548.00 Crore) operating in Phar...
- Buy Zydus Lifesciences., target price Rs 426: Angel OnePromoters held 74.98 per cent stake in the company as of 30-Sep-2022, while FIIs owned 2.86 per cent, DIIs 12.85 per cent.
- CLSA retains buy on Cadila Healthcare, raises target price to Rs 330The brokerage has raised earnings estimates by 2-10% to reflect the strong earnings beat in the third quarter.
- Buy Cadila Healthcare, price target Rs 295: Kunal BothraThe analyst suggested a stoploss at Rs 250.
- Buy Cadila Healthcare, price target Rs 278: Sagar DoshiThe analyst suggested a stoploss at Rs 245.
- Buy Cadila Healthcare, target Rs 248: Sagar DoshiBuy Cadila Healthcare Ltd. at a price target of Rs 248.0 and a stoploss at Rs 216 from entry point.
- Sell Cadila Healthcare, target Rs 373: Dharmesh ShahSell Cadila Healthcare Ltd. at a price target of Rs 373.0 and a stop loss at Rs 402 from entry point.
- Buy Cadila Healthcare, target Rs 435: Manas JaiswalBuy Cadila Healthcare Ltd. at a price target of Rs 435.0 and a stop loss at Rs 419 from entry point.
- Sell Cadila Healthcare, target Rs 445: Manas JaiswalSell Cadila Healthcare at a price target of Rs 445 and a stop loss at Rs 470 from entry point.
- Pankaj Patel steps down as Cadila MD, son Sharvil to take overThe Board of Directors of Cadila Healthcare has unanimously approved the appointment of Sharvil P Patel as the Manging Director of the comp...
- Zydus Cadila launches biosimilar of AbbVie's Humira in IndiaZydus Cadila today launched biosimilar of Adalimumab, used for treatment of auto immune disorders, at a price much lower than the innovator...
Load More
